PA · BOI.PA
Boiron S.A.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Messimy 69510
- Website
- boiron.fr
Price · as of 2024-12-31
$27.40
Market cap 469.65M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $44.27 | +61.57% |
| Intrinsic Value(DCF) | $9.22 | -66.35% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $4.56 | -83.36% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $15.45 | $72.43 | $3.77 | $11.40 | $14.47 |
| 2011 | $13.80 | $52.12 | $3.70 | $12.32 | $17.14 |
| 2012 | $21.94 | $48.26 | $6.42 | $13.58 | $37.25 |
| 2013 | $32.92 | $95.32 | $23.91 | $23.38 | $71.84 |
| 2014 | $56.37 | $116.71 | $18.13 | $20.10 | $32.27 |
| 2015 | $41.20 | $106.66 | $16.39 | $15.34 | $31.05 |
| 2016 | $51.47 | $118.30 | $18.14 | $19.29 | $38.32 |
| 2017 | $44.55 | $114.17 | $20.04 | $20.44 | $36.14 |
| 2018 | $33.26 | $109.50 | $16.43 | $14.56 | $19.46 |
| 2019 | $18.65 | $90.73 | $10.63 | $13.60 | $1.55 |
| 2020 | $23.61 | $58.26 | $12.42 | $15.70 | $1.00 |
| 2021 | $27.08 | $92.94 | $11.37 | $19.14 | $0.00 |
| 2022 | $28.82 | $57.07 | $12.24 | $25.27 | $63.64 |
| 2023 | $29.71 | $82.74 | $1.84 | $0.00 | $1.78 |
| 2024 | $23.05 | $44.27 | $0.00 | $0.00 | $4.56 |
AI valuation
Our deep-learning model estimates Boiron S.A.'s (BOI.PA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $44.27
- Current price
- $27.40
- AI upside
- +61.57%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$9.22
-66.35% upside
Graham-Dodd
—
— upside
Graham Formula
$4.56
-83.36% upside
About Boiron S.A.
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
- CEO
- Thierry Boiron
- Employees
- 2.47K
- Beta
- 0.30
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($9.22 ÷ $27.40) − 1 = -66.35% (DCF, example).